Xeris Biopharma Statistics
Share Statistics
Xeris Biopharma has 160.16M
shares outstanding. The number of shares has increased by 3.83%
in one year.
| Shares Outstanding | 160.16M |
| Shares Change (YoY) | 3.83% |
| Shares Change (QoQ) | 3.26% |
| Owned by Institutions (%) | 43.96% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 14 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 17.23M, so 10.76% of the outstanding
shares have been sold short.
| Short Interest | 17.23M |
| Short % of Shares Out | 10.76% |
| Short % of Float | 11.19% |
| Short Ratio (days to cover) | 8.2 |
Valuation Ratios
The PE ratio is -9.07 and the forward
PE ratio is 40.62.
Xeris Biopharma's PEG ratio is
0.51.
| PE Ratio | -9.07 |
| Forward PE | 40.62 |
| PS Ratio | 2.45 |
| Forward PS | 1.6 |
| PB Ratio | -16.8 |
| P/FCF Ratio | -13.15 |
| PEG Ratio | 0.51 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Xeris Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.67,
with a Debt / Equity ratio of -9.17.
| Current Ratio | 1.67 |
| Quick Ratio | 1.19 |
| Debt / Equity | -9.17 |
| Debt / EBITDA | -24.01 |
| Debt / FCF | -7.17 |
| Interest Coverage | -1.01 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $515,406.09 |
| Profits Per Employee | $-139,177.66 |
| Employee Count | 394 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 0.76 |
Taxes
| Income Tax | -2.27M |
| Effective Tax Rate | 3.97% |
Stock Price Statistics
The stock price has increased by 150.78% in the
last 52 weeks. The beta is 0.91, so Xeris Biopharma's
price volatility has been higher than the market average.
| Beta | 0.91 |
| 52-Week Price Change | 150.78% |
| 50-Day Moving Average | 4.78 |
| 200-Day Moving Average | 3.62 |
| Relative Strength Index (RSI) | 52.96 |
| Average Volume (20 Days) | 3,128,819 |
Income Statement
In the last 12 months, Xeris Biopharma had revenue of 203.07M
and earned -54.84M
in profits. Earnings per share was -0.37.
| Revenue | 203.07M |
| Gross Profit | 166.24M |
| Operating Income | -33.65M |
| Net Income | -54.84M |
| EBITDA | -11.3M |
| EBIT | -26.62M |
| Earnings Per Share (EPS) | -0.37 |
Full Income StatementBalance Sheet
The company has 71.62M in cash and 271.45M in
debt, giving a net cash position of -199.83M.
| Cash & Cash Equivalents | 71.62M |
| Total Debt | 271.45M |
| Net Cash | -199.83M |
| Retained Earnings | -671.86M |
| Total Assets | 315.45M |
| Working Capital | 68.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -36.98M
and capital expenditures -868K, giving a free cash flow of -37.85M.
| Operating Cash Flow | -36.98M |
| Capital Expenditures | -868K |
| Free Cash Flow | -37.85M |
| FCF Per Share | -0.26 |
Full Cash Flow StatementMargins
Gross margin is 81.86%, with operating and profit margins of -16.57% and -27%.
| Gross Margin | 81.86% |
| Operating Margin | -16.57% |
| Pretax Margin | -28.12% |
| Profit Margin | -27% |
| EBITDA Margin | -5.57% |
| EBIT Margin | -16.57% |
| FCF Margin | -18.64% |
